Renaissance Technologies’s Juniper Pharmaceuticals, Inc. Common Stock JNP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q3
Sell
-752,173
Closed -$6.54M 3694
2018
Q2
$6.54M Buy
752,173
+91,623
+14% +$824K 0.01% 1607
2018
Q1
$6.71M Buy
660,550
+123,100
+23% +$1.03M 0.01% 1624
2017
Q4
$2.61M Buy
537,450
+86,800
+19% +$422K ﹤0.01% 2183
2017
Q3
$2.05M Buy
450,650
+49,050
+12% +$230K ﹤0.01% 2291
2017
Q2
$2.03M Buy
401,600
+92,100
+30% +$412K ﹤0.01% 2258
2017
Q1
$1.47M Buy
309,500
+55,200
+22% +$279K ﹤0.01% 2391
2016
Q4
$1.42M Buy
254,300
+17,900
+8% +$98.3K ﹤0.01% 2387
2016
Q3
$1.31M Buy
236,400
+16,500
+8% +$109K ﹤0.01% 2429
2016
Q2
$1.54M Buy
219,900
+17,000
+8% +$120K ﹤0.01% 2346
2016
Q1
$1.34M Buy
202,900
+15,300
+8% +$113K ﹤0.01% 2439
2015
Q4
$1.93M Buy
187,600
+30,900
+20% +$358K ﹤0.01% 2136
2015
Q3
$1.85M Sell
156,700
-30,176
-16% -$333K ﹤0.01% 2047
2015
Q2
$1.71M Buy
186,876
+516
+0.3% +$3.9K ﹤0.01% 2160
2015
Q1
$1.16M Buy
186,360
+75,354
+68% +$466K ﹤0.01% 2232
2014
Q4
$622K Buy
111,006
+12,056
+12% +$70.2K ﹤0.01% 2358
2014
Q3
$583K Buy
98,950
+4,200
+4% +$25.6K ﹤0.01% 2257
2014
Q2
$649K Sell
94,750
-29,300
-24% -$196K ﹤0.01% 2214
2014
Q1
$894K Sell
124,050
-40,200
-24% -$278K ﹤0.01% 2127
2013
Q4
$1.09M Sell
164,250
-20,700
-11% -$141K ﹤0.01% 2043
2013
Q3
$1.34M Buy
+184,950
New +$1.24M ﹤0.01% 1869

Renaissance Technologies's JNP Position: Q3 2018 in Review

Renaissance Technologies sold out of Juniper Pharmaceuticals, Inc. Common Stock (JNP) in Q3 2018, closing a stake of 752,173 shares — an estimated $6.54M sold.

Renaissance Technologies first reported a position in JNP in Q3 2013 and held it in 20 quarters. The position peaked at $6.71M in Q1 2018. 0 funds tracked by Wall St. Rank hold JNP as of Q3 2018.

  • Renaissance Technologies reported no remaining Juniper Pharmaceuticals, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Renaissance Technologies sold 752,173 Juniper Pharmaceuticals, Inc. Common Stock shares in Q3 2018, an estimated $6.54M.
  • Renaissance Technologies first reported a position in Juniper Pharmaceuticals, Inc. Common Stock in Q3 2013 and held it in 20 quarters.
  • Renaissance Technologies's Juniper Pharmaceuticals, Inc. Common Stock position peaked at $6.71M in Q1 2018.
  • 0 funds tracked by Wall St. Rank held Juniper Pharmaceuticals, Inc. Common Stock as of Q3 2018.

Based on Renaissance Technologies's 13F filing for Q3 2018, filed 13 Nov 2018.